USPTO serial 79440662
ISOMORPHIC LABS
Reviewed by CopyMark Law Group
Status 661
- Filing date
- Status date
- Registration date
- —
- Examiner
- LE, KIEU-NHI NGOC
- Law office
- TMO LAW OFFICE 129
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with ISOMORPHIC LABS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Cynthia Walden
Cynthia Walden Fish & Richardson P.C.P.O. Box 1022Minneapolis, MN 55440-1022United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations for the treatment of systemic inflammatory and immunological conditions; pharmaceutical preparations for the treatment of oncological and hematological diseases; pharmaceutical preparations for metabolic and endocrine disorders; pharmaceutical preparations for neurological diseases; and pharmaceutical preparations for infectious diseases | ACTIVE | — |
| 009 | apparatus and instruments for recording, transmitting, reproducing or processing sound, images or data; downloadable computer software for use in manipulating received or inputted data generated in in a virtual space for use in connection with artificial intelligence methods, natural language processing, natural language understanding, dialog systems, voice and speech recognition and text to speech systems, natural language human-machine interfaces, predictive assistance technologies; blank digital and analogue recording storage media; downloadable computer software using artificial intelligence, machine learning, deep learning, and reinforcement learning for use in protein structure prediction, pharmaceutical drug discovery, and pharmaceutical product development; downloadable computer software applications for use in designing and developing artificial intelligence, information technology, deep learning, machine learning, and reinforcement learning for use in protein structure prediction, pharmaceutical drug discovery, and pharmaceutical product development; downloadable computer software, computer programs and algorithms for use in manipulating received or inputted data generated in in a virtual space for use in connection with artificial intelligence methods, natural language processing, natural language understanding, dialog systems, voice and speech recognition and text to speech systems, natural language human-machine interfaces, predictive assistance technologies; recorded computer programs using artificial intelligence, machine learning, deep learning, and reinforcement learning for use in software development in the field of protein structure prediction, pharmaceutical drug discovery, and pharmaceutical product development. | ACTIVE | — |
| 042 | Scientific and technological services and research and design relating thereto in the field of medical research, pharmaceutical research, protein structure prediction, pharmaceutical drug discovery, and pharmaceutical product development; industrial analysis and industrial research services in the field medical research, pharmaceutical research, protein structure prediction, pharmaceutical drug discovery, and pharmaceutical product development; design and development of computer hardware and software; software as a service [saas] services featuring software using artificial intelligence, machine learning, deep learning, and reinforcement learning for use in protein structure prediction, pharmaceutical drug discovery, and pharmaceutical product development; advanced product research, design and development in the field of artificial intelligence; scientific research and development in the fields of artificial intelligence, machine learning, deep learning, and reinforcement learning; technology research in the field of artificial intelligence, machine learning, deep learning, and reinforcement learning for use in protein structure prediction, pharmaceutical drug discovery, and pharmaceutical product development; computer software development in the field of artificial intelligence, machine learning, deep learning, and reinforcement learning for use in protein structure prediction, pharmaceutical drug discovery, and pharmaceutical product development; software development consulting in the field of artificial intelligence, machine learning, deep learning, and reinforcement learning for use in protein structure prediction, pharmaceutical drug discovery, and pharmaceutical product development; Providing online non-downloadable computer software platforms using artificial intelligence, machine learning, deep learning, and reinforcement learning for use in protein structure prediction, pharmaceutical drug discovery, and pharmaceutical product development; development and testing of computing methods, algorithms, computer software, and computer hardware; scientific, pharmaceutical, and medical research for use in protein structure prediction, pharmaceutical drug discovery, and pharmaceutical product development; scientific research in the field of computer software using artificial intelligence, machine learning, deep learning, and reinforcement learning for use in medical research, pharmaceutical research, protein structure prediction, pharmaceutical drug discovery, and pharmaceutical product development; product research and development; medical, pharmaceutical, and scientific research in the field of protein structure prediction, pharmaceutical drug discovery, pharmaceutical product development, and computational biology; scientific and technological services, namely, scientific and technical consulting, scientific research, development and design of computer software and technology in the fields of analytics and data mining, data analysis, data transformation, data visualization, statistical analysis, artificial intelligence, machine learning and virtual reality, science, chemistry, physics, biology and scientific research and new product design services provided in connection with the foregoing; computer aided scientific analysis in the field of artificial intelligence, machine learning, deep learning, reinforcement learning, building neural networks, tree search, high performance computing, distributed computing, cloud computing, analytics and data mining, virtual reality, augmented reality, science, chemistry, physics, biology; computer modelling services; scientific services for the analysis of organic compounds namely, medical research, pharmaceutical research, protein structure prediction, pharmaceutical drug discovery, and pharmaceutical product development; drug discovery services. | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 4, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 4, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 4, 2026 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 1, 2026 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Apr 1, 2026 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 1, 2026 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Apr 1, 2026 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Apr 1, 2026 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Mar 19, 2026 | RFNT | REFUSAL PROCESSED BY IB | — |
| Mar 5, 2026 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Mar 5, 2026 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Feb 4, 2026 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Feb 3, 2026 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 29, 2026 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 7, 2026 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jan 7, 2026 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jan 1, 2026 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |